CVS HEALTH CORPORATION (CVS) FY2024 Annual P&L / Income Statement

CVS HEALTH CORPORATION (CVS) FY2024 Annual P&L / Income Statement

Income statement for 2024-01-01 through 2024-12-31. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

372,809,000,000 US dollars

Total operating costs

364,293,000,000 US dollars

Operating income

8,516,000,000 US dollars

Other income (expense), net (calculated)

negative 2,368,000,000 US dollars

Income before income tax provision

6,148,000,000 US dollars

Income tax provision

1,562,000,000 US dollars

Net income

4,586,000,000 US dollars

Health Care Benefits

130,665,000,000 US dollars

Health Services

173,605,000,000 US dollars

Pharmacy & Consumer Wellness

124,500,000,000 US dollars

Cost of products sold

206,287,000,000 US dollars

Health care costs

115,121,000,000 US dollars

Operating expenses

41,606,000,000 US dollars

Restructuring charges

1,179,000,000 US dollars

Opioid litigation charges

100,000,000 US dollars

Loss on assets held for sale

0 US dollars

Revenue before reconciliation (calculated)

428,770,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.

Health Care Benefits

negative 72,000,000 US dollars. Reported reconciliation to consolidated revenue.

Health Services

negative 15,304,000,000 US dollars. Reported reconciliation to consolidated revenue.

Pharmacy & Consumer Wellness

negative 41,036,000,000 US dollars. Reported reconciliation to consolidated revenue.

Corporate/ Other

451,000,000 US dollars. Reported reconciliation to consolidated revenue.

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
• Of which attributable to CVS HEALTH CORPORATION: $4.61 B; to noncontrolling interests: −$28.00 M.